



03-08-02

03CD
4

CASE 4-30957A/C1(B/M)

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV041586231US
Express Mail Label NumberMarch 7, 2002
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

SCHUURMAN ET AL.

APPLICATION NO: 10/035,663

FILED: NOVEMBER 7, 2001

FOR: COMBINATIONS OF IMMUNOSUPPRESSIVE AGENTS FOR THE
TREATMENT OR PREVENTION OF GRAFT REJECTIONSAssistant Commissioner for Patents
Washington, D.C. 20231INFORMATION DISCLOSURE STATEMENT


Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6765

Date: March 7, 2002

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Sheet 1 of 3

ATTY. DOCKET NO.
4-30957/A/C1(B/+)
APPLICATION NO.
10/035,663
APPLICANT
SCHUURMAN ET AL.
FILING DATE
NOVEMBER 7, 2001

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA	5,593,677	1/14/97	Reichert et al.	424	154.1	5/26/94
AB	5,631,282	5/20/97	Goetz	514	450	6/7/95
AC	5,651,968	7/29/97	Good et al.	424	140.1	8/21/92
AD	5,665,728	9/9/97	Morris et al.	514	291	5/26/95
AE	5,688,824	11/18/97	Williams	514	378	2/7/96
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES <input type="checkbox"/> <input checked="" type="checkbox"/>	NO <input checked="" type="checkbox"/> <input type="checkbox"/>
• AM	WO92/00739	1/23/92	WIPO			<input type="checkbox"/>	<input checked="" type="checkbox"/>
• AN	WO93/03735	3/4/93	WIPO			<input type="checkbox"/>	<input checked="" type="checkbox"/>
• AO	WO97/35575	10/2/97	WIPO			<input type="checkbox"/>	<input checked="" type="checkbox"/>
• AP	WO97/38689	10/23/97	WIPO			<input type="checkbox"/>	<input checked="" type="checkbox"/>
• AQ	WO98/04279	2/5/98	WIPO			<input type="checkbox"/>	<input checked="" type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

• AR	Buhler et al., "Xenotransplantation - State of the Art - Update 1999", Frontiers in Bioscience, Vol. 4, pp. d416-432 (1999).
• AS	Fujino et al., "Evaluation of Cyclosporine, Mycophenolate Mofetil, and Brequinar Sodium Combination Therapy on Hamster-To-Rat Cardiac Xenotransplantation", Transplantation, Vol. 57, No. 1, pp. 41-46 (1994).
• AT	Halloran et al., "Molecular Mechanisms of New Immunosuppressants", Clin. Transplantation, Vol. 10, pp. 118-123 (1996).

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30957A/C1(B+)
APPLICATION NO.
10/035,663
APPLICANT
SCHUURMAN ET AL.
FILING DATE
NOVEMBER 7, 2001

Group

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRANSLATION YES <input type="checkbox"/> NO <input type="checkbox"/>
AA	WO98/11894	3/26/98	WIPO			
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						
AM						
AN						
AO						
AP						
AQ						
AR						
AS						
AT						
AU						
AV						
AW						
AX						
AY						
AZ						
EXAMINER			DATE CONSIDERED			

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.

4-30957A/C1(B/+)

APPLICATION NO.

10/035,663

APPLICANT

SCHURMAN ET AL.

FILING DATE

NOVEMBER 7, 2001

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Hulett et al., "Prolongation of Allograft and Xenograft Survival With Mycophenolate Mofetil (RS-61443) and Brequinar Sodium (DUP-785)", Transplant Proceedings, Vol. 25, No. 1, pp. 700-701 (1993).
AB	Schurman et al., "SDZ RAD, A New Rapamycin Derivative", Transplantation, Vol. 64, No. 1, pp. 32-35 (1997).
AC	Tu et al., "The Synergistic Effects of Cyclosporine, Sirolimus, and Brequinar on Heart Allograft Survival in Mice", Transplantation, Vol. 59, No. 2, pp. 177-189 (1995).
AD	Waterworth et al., "Life-Supporting Pig-To-Baboon Heart Xenotransplantation", J. Heart and Lung Transplant., Vol. 17, No. 12, pp. 1201-1207 (1998).
AE	Wennberg et al., "Immunosuppression With Cyclosporin A in Combination with Leflunomide and Mycophenolate Mofetil Prevents Rejection of Pig-Islets Transplanted into Rats", Transplant. Proceedings, Vol. 28, No. 2, p. 819 (1996).
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 608: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.